Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a simple urine test predict who benefits from PH treatment?

NCT ID NCT07254338

Knowledge-focused Sponsor: Hospices Civils de Lyon Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at small molecules (metabolites) in the blood and urine of people with pulmonary hypertension caused by lung fibrosis. Researchers want to see how these metabolites change with treatment and whether they can tell who will respond well. The goal is to better understand how treatments work and to avoid giving ineffective therapies to fragile patients.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could help doctors predict which patients will benefit from PH treatments, reducing side effects and improving outcomes.
What could go wrong
This is an early exploratory study with only 80 participants, focused on biomarkers rather than direct treatment effects. Results may not change clinical practice immediately.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 80 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2026

Expected to finish

Aug 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult patients monitored at Hospices Civils de Lyon for Interstitial Lung Disease, with suspected group 3 PH, for whom the medical team is considering or discussing the indication for specific ILD-PH treatment.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients suffering from progressive interstitial lung disease (ILD) and especially lung fibrosis * Suspicion of precapillar pulmonary hypertension (group 3 PH / ILD-PH) * Patients undergoing cardiac catheterisation for haemodynamic confirmation * Patient who has given informed consent Exclusion Criteria: * Patients suffering from other forms of PH (i.e. PAH, CTEPH, heart failure, multifactorial

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Interstitial lung disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

interstitial lung disease pulmonary hypertension

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Interstitial lung disease Precapillar pulmonary hypertension

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Hôpital Cardiologique et Pneumologique Louis Pradel

    RECRUITING

    Bron, Rhone, 69500, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.